Abbvie Inc DRC (ABBVm)

Currency in ARS
24,025.00
+350.00(+1.48%)
Delayed Data·
ABBVm Scorecard
Full Analysis
Has raised its dividend for 12 consecutive years
ABBVm is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
23,750.0024,025.00
52 wk Range
18,325.0027,925.00
Key Statistics
Bid/Ask
24,025.00 / 24,100.00
Prev. Close
23,675
Open
23,775
Day's Range
23,750-24,025
52 wk Range
18,325-27,925
Volume
189
Average Volume (3m)
1.88K
1-Year Change
2.6%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ABBVm Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Abbvie Inc DRC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Abbvie Inc DRC Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Employees
55000
Market
Argentina

Compare ABBVm to Peers and Sector

Metrics to compare
ABBVm
Peers
Sector
Relationship
P/E Ratio
79.5x−2.9x−0.5x
PEG Ratio
−2.620.040.00
Price/Book
232.8x2.6x2.6x
Price / LTM Sales
5.8x8.1x3.2x
Upside (Analyst Target)
-33.9%42.7%
Fair Value Upside
Unlock20.9%5.8%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.35%
Dividend Yield
3.50%
Industry Median 2.83%
Annualised payout
828.20
Paid quarterly
5-Years Growth
+7.23%
Growth Streak

Earnings

Latest Release
May 09, 2025
EPS / Forecast
0.72 / --
Revenue / Forecast
13.34B / --
EPS Revisions
Last 90 days

ABBVm Income Statement

People Also Watch

12,050.00
CVXm
+1.69%
8,100.00
PFEm
+1.89%
13,400.00
PGm
+0.38%
9,200.00
ABEVm
+2.91%
39,550.00
ABTm
-0.63%

FAQ

What Stock Exchange Does Abbvie Trade On?

Abbvie is listed and trades on the Buenos Aires Stock Exchange stock exchange.

What Is the Stock Symbol for Abbvie?

The stock symbol for Abbvie is "ABBVm."

What Is the Abbvie Market Cap?

As of today, Abbvie market cap is 422.08T.

What Is Abbvie's Earnings Per Share (TTM)?

The Abbvie EPS (TTM) is 2.35.

From a Technical Analysis Perspective, Is ABBVm a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Abbvie Stock Split?

Abbvie has split 0 times.

How Many Employees Does Abbvie Have?

Abbvie has 55000 employees.

What is the current trading status of Abbvie (ABBVm)?

As of 23 Jul 2025, Abbvie (ABBVm) is trading at a price of 24,025.00, with a previous close of 23,675.00. The stock has fluctuated within a day range of 23,750.00 to 24,025.00, while its 52-week range spans from 18,325.00 to 27,925.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.